"Calcium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
| Descriptor ID |
D002121
|
| MeSH Number(s) |
D27.505.519.562.249 D27.505.954.411.192
|
| Concept/Terms |
Calcium Channel Blockers- Calcium Channel Blockers
- Blockers, Calcium Channel
- Channel Blockers, Calcium
- Calcium Channel Antagonists
- Antagonists, Calcium Channel
- Calcium Channel Blocking Drugs
Calcium Antagonists, Exogenous- Calcium Antagonists, Exogenous
- Antagonists, Exogenous Calcium
- Exogenous Calcium Inhibitors
- Exogenous Calcium Antagonists
- Exogenous Calcium Blockaders
- Calcium Blockaders, Exogenous
- Calcium Inhibitors, Exogenous
|
Below are MeSH descriptors whose meaning is more general than "Calcium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Calcium Channel Blockers".
This graph shows the total number of publications written about "Calcium Channel Blockers" by people in this website by year, and whether "Calcium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 9 | 16 | 25 |
| 2018 | 8 | 11 | 19 |
| 2019 | 3 | 11 | 14 |
| 2020 | 5 | 3 | 8 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Calcium Channel Blockers" by people in Profiles.
-
Synthesis of novel calcium channel blockers with ACE2 inhibition and dual antihypertensive/anti-inflammatory effects: A possible therapeutic tool for COVID-19. Bioorg Chem. 2021 11; 116:105272.
-
Renin-Angiotensin Aldosterone System Inhibitors in Primary Prevention and COVID-19. J Am Heart Assoc. 2021 08 03; 10(15):e021154.
-
Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis. Diabetes Metab Syndr. 2021 Sep-Oct; 15(5):102210.
-
Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea. Yonsei Med J. 2021 Jul; 62(7):577-583.
-
Case Report: Systemic Sclerosis After Covid-19 Infection. Front Immunol. 2021; 12:686699.
-
Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension. Chin Med J (Engl). 2021 Jun 16; 134(13):1602-1609.
-
Renin-angiotensin-aldosterone system inhibitors and SARS-CoV-2 infection: an analysis from the veteran's affairs healthcare system. Am Heart J. 2021 10; 240:46-57.
-
Comparison of renin-angiotensin-aldosterone system inhibitors with other antihypertensives in association with coronavirus disease-19 clinical outcomes. BMC Infect Dis. 2021 Jun 05; 21(1):527.
-
The Discovery of Naringenin as Endolysosomal Two-Pore Channel Inhibitor and Its Emerging Role in SARS-CoV-2 Infection. Cells. 2021 05 07; 10(5).
-
Outcomes of Hospitalized COVID-19 Patients Receiving Renin Angiotensin System Blockers and Calcium Channel Blockers. Am J Nephrol. 2021; 52(3):250-260.